OS Therapies (OSTX) said late Monday it has terminated its equity purchase agreement with Square Gate Capital Master Fund, effective Aug. 26.
Chairman and Chief Executive Paul Romness said its recent warrant exercise inducement and exchange offering provided the company with $4.2 million in gross proceeds to fund operations into mid-2026.
"[O]ur projected monthly burn in the second half of 2025 is significantly less than it was in the first half of 2025," he said.
Shares of the cancer-focused biotech company were up 3.7% in after-market activity.
Price: 2.27, Change: +0.08, Percent Change: +3.65
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.